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A randomized controlled study of iron supplementation in patients
treated with erythropoietin. In view of current uncertainty regarding the
optimum route for iron supplementation in patients receiving recombi-
nant human erythropoietin (EPO), a prospective randomized controlled
study was designed to investigate this issue. All iron-replete renal failure
patients commencing EPO who had a hemoglobin concentration < 8.5
g/dl and an initial serum ferritin level of 100 to 800 pg/liter were
randomized into three groups with different iron supplementation: Group
1, iv. iron dextran 5 ml every 2 weeks; Group 2, oral ferrous sulphate 200
mg tds; Group 3, no iron. All patients were treated with 25 U/kg of EPO
thrice weekly subcutaneously. The hemoglobin concentration, reticulocyte
Count, serum ferritin, transferrin saturation, and EPO dose were moni-
tored every two weeks for the first four months. Thirty-seven patients
entered the study (12 i.v., 13 oral, 12 no iron). The three groups were
equivalent with regard to age, sex, and other demographic details. Even
allowing for dosage adjustments, the hemoglobin response in the group
receiving i.v. iron (7.3 0.8 to 11.9 1.2 g/dl) was significantly greater
than that for the other two groups (7.2 1.1 to 10.2 1.4 gIdl and 7.3
0.8 to 9.9 1.6 g/dl for Groups 2 and 3, respectively; P < 0.005 for both
groups vs. Group 1 at 16 weeks). There was no difference between the
groups supplemented with oral iron and no iron. Serum ferritin levels
remained constant in those receiving i.v. iron (345 273 to 359 140
J.Lglliter), in contrast to the other two groups in which ferritin levels fell
significantly (309 218 to 116 87 j.g/liter and 458 206 to 131 121
pg/liter for Groups 2 and 3, respectively; P < 0.0005 for Group 1 vs.
Group 2, and P < 0.005 for Group 1 vs. Group 3 at 16 weeks). Dosage
requirements of EPO were less in Group 1(1202 229 U/kgIl6 weeks)
than in Group 2 (1294 314 U/kg/16 weeks) or Group 3 (1475 311
U/kg/16 weeks; P < 0.05 vs. Group 1). The results of this study suggest
that, even in iron-replete patients, those supplemented with i.v. iron have
an enhanced hemoglobin response to EPO with better maintenance of
iron stores and lower dosage requirements of EPO, compared with those
patients receiving oral iron and no iron supplementation.
Anecdotal reports from even the earliest clinical trials of
recombinant human erythropoietin (EPO) suggested problems
with iron deficiency in patients receiving this treatment. Eschbach
and colleagues [1] were the first to draw attention to this problem,
with 12 of 25 patients being given intravenous iron dextran as
additional iron supplementation. Further studies confirmed this
observation [2—51, and it soon became apparent that large
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amounts of iron were required to support erythropoiesis in
patients receiving EPO. Iron supplementation became widely
used in such patients, and indeed, most patients starting EPO are
now routinely given iron supplements in one form or another [6].
However, the value of this practice has never been assessed by
prospective controlled clinical trial.
There has also been much controversy as to whether such iron
supplementation is best given orally or intravenously, and in
particular whether oral iron supplements can keep pace with the
demand. Some authors have found that in the majority of patients
oral iron supplementation is adequate [7], while others report a
requirement for intravenous iron in a significant proportion of
patients treated with EPO [4, 5, 8, 9].
Part of the problem is that there is no reliable marker of
functional iron deficiency in patients receiving EPO. The serum
ferritin provides a reasonable indicator of iron stores [10], and
indeed if this falls below a level of about 30 to 50 rg/Iiter then
absolute iron deficiency is unequivocally present [11]. Functional
iron deficiency, however, is now well-recognized in patients
receiving EPO, who have adequate iron stores (as judged by a
normal serum ferritin level) but who are unable to mobilize iron
from these stores rapidly enough to satisfy the demands of the
bone marrow [1—3, 6]. The transferrin saturation is theoretically a
better indicator of available iron since it reflects the amount of
circulating iron in relation to its binding protein in plasma [121.
Previous studies suggested that once the transferrin saturation
falls below 16 to 20% then the iron supply for eiythropoiesis will
be inadequate [13]. However, there is considerable diurnal vari-
ation in this biological parameter even in normal subjects [14], so
that a value of < 20% may not always indicate iron insufficiency.
Other methods of assessing functional iron deficiency have been
reported, such as the percentage of hypochromic red cells in the
circulation [15, 16], red cell ferritin [17], free erythrocyte proto-
porphyrin [18], and red cell zinc protoporphyrin levels [19]. Of
these, measurement of the percentage of hypochromic red cells is
perhaps the most useful since it is an indirect measure of the
adequacy of iron supply to the red cell for incorporation into
hemoglobin [15, 16]. None of the other tests has proved ideal, and
the true incidence of functional iron deficiency in patients receiv-
ing EPO is unknown.
It is also possible that, under EPO stimulation, iron supply to
the marrow may be a rate-limiting step in the process of erythro-
poiesis. If so, then administering iron in a readily available form
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(such as intravenous iron dextran) may enhance the hemopoietic
response to EPO even in patients who are iron-replete.
To investigate these issues, we set up a prospective randomized
controlled study of iron supplementation in iron-replete patients
receiving EPO therapy, to compare the effects of using three
different regimens of iron treatment: (i) regular intravenous iron
supplementation; (ii) regular oral iron supplementation; and (iii)
no iron supplementation.
Methods
Patients
Any patient with renal anemia starting EPO therapy was
eligible for the study provided they met the following inclusion
criteria: (i) Patients on regular hemodialysis (stable for  3
months), those on CAPD (stable for  3 months), patients
approaching end-stage renal failure but who had not yet com-
menced renal replacement therapy. (ii) Hemoglobin concentra-
tion  8.5 g/dl on 3 successive occasions. (iii) Normal serum B12;
normal serum and red cell folate levels. (iv) Serum ferritin 100 to
800 jig/liter. (v) No other cause for anemia, such as SLE,
rheumatoid arthritis, myeloma. (vi) Absence of infection, malig-
nancy, or surgery in last 3 months. (vii) Serum C-reactive pro-
tein < 10 mg/liter. (viii) No evidence of severe hyperparathyroid-
ism (that is, plasma PTH < 100 pmol/liter) or aluminium toxicity
(plasma aluminium 0.4 jsmol/liter). (ix) Adequate BP control
prior to treatment (< 140/90 mm Hg).
Study protocol
The study was approved by the Ethics Committee of St Bar-
tholomew's Hospital.
(i) EPO. All patients were treated with an initial dose of 25
U/kg three times weekly given subcutaneously. In order to mini-
mize the number of dosage adjustments to allow direct compari-
son of the hemoglobin response among the three groups of
patients, this dose was maintained for at least 8 weeks unless the
hemoglobin had increased to above 12 g/dl. If this target level was
exceeded at any stage of the study, the dose of EPO employed was
reduced by one-third; if there had been no significant rise in the
hemoglobin concentration (< 1 g/dl) by 8 weeks onwards then the
dose of EPO was doubled.
(ii) Iron supplementation. After giving informed consent, pa-
tients were randomized to one of three groups: Group 1 patients
received an intravenous infusion of iron dextran (Imferon; Fisons
Pharmaceuticals, Loughborough, UK) 5 ml, diluted in 100 ml of
0.9% sodium chloride, every two weeks (equivalent to 250 mg of
elemental iron). A test dose was given at the start of i.v. iron
treatment to check for any possible allergy or anaphylaetoid
reaction by administering no more than 20 ml of the infusion over
the first five minutes. The rate of infusion was then very slowly
increased, and the first dose was given over 40 minutes. Subse-
quent doses were administered over 25 to 30 minutes. Full
resuscitation facilities including adrenaline, steroids, and antihis-
tamines were at hand during every infusion of i.v. iron.
Group 2 patients were treated with oral ferrous sulphate 200
mg tds. Compliance was assessed by direct questioning of the
patient at each fortnightly visit to the clinic, and by examining the
prescribed medication for the number of remaining tablets.
Patients were instructed to take their iron tablets with meals to
Table 1. Demographic details of the three groups of patients included
in the study
Intravenous Fe Oral Fc No Fe
No. of patients 12 13 12
Sex ÔM, 6F 8M, SF 7M, 5F
Age years 47 15 58 16 54 10
Mode of RRT 4 HD
7CAPD
1 pre-dialysis
6 HD
5CAPD
2 pre-dialysis
5 HD
7CAPD
Pre-treatment Hb g/dl 7.3 0.8 7.2 1.1 7.3 0.8
Pre-treatment ferritin jig/liter 345 273 309 218 458 206
(119—790) (140—760) (120—750)
minimize side-effects such as nausea, and were also told to avoid
simultaneous administration of phosphate binders.
Group 3 patients were given no iron supplementation.
Assessment
Patients were seen in the outpatient clinic every two weeks
throughout the four-month study period. They were questioned
regarding their compliance with EPO and oral iron (if relevant),
and about the development of any possible side-effects of the
treatment. Their blood pressure and weight were checked, and
antihypertensive medication was adjusted as required. The cur-
rent dose of EPO was recorded, and blood was taken for
measurement of the following (prior to i.v. iron infusion if
relevant): (i) full blood count; (ii) reticulocyte count; (iii) serum
ferritin; (iv) serum iron and total iron binding capacity.
End-points
The study was terminated at four months since by then it was
anticipated that most patients would have achieved their target
hemoglobin concentration. The principal end-points of the study
were: (i) hemoglobin response, (ii) iron status, (iii) EPO dosage
requirements.
Statistics
Results are expressed as mean so. Analysis of variance and
unpaired t-tests were used to compare the data at each time point
between Groups 1 and 2, Groups I and 3, and Groups 2 and 3. A
P value of less than 0.05 was considered significant.
Results
Patients
Thirty-eight patients were enrolled in the study over a 12 month
period. One male hemodialysis patient had a mild anaphylactoid
reaction during his first infusion of i.v. iron; this precluded further
administration of intravenous iron and he was excluded from
further analysis. The remaining 37 patients were randomized as
follows: (i) i.v. iron; 12 patients (Group 1); (ii) oral iron; 13
patients (Group 2); (iii) no iron; 12 patients (Group 3).
The three groups were similar with regard to age, sex, and other
demographic details (Table 1).
Dosage adjustment of EI'C)
Despite every attempt to avoid alterations in the dose of EPO,
this became necessary in no fewer than 19 of the patients in the
study (Table 2). Ten of the patients required an increase in EPO
dose due to an inadequate hemoglobin response, 18 of the
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Intravenous Fe
(N = 12)
Oral Fe
(N = 13)
No Fe
(N = 12)
tDose 1
(8 weeks)
3
(8, 8, 10 weeks)
6
(8, 8, 8, 10, 10,
14 weeks)
No change in 6 6 6
dose
Dose 5
(6, 10, 10, 14,
16 weeks)
4
(8, 10, 12, 12 weeks)
0
patients were able to maintain the same dose for the entire
duration of the study, and the remaining 9 patients had their dose
of EPO reduced when their hemoglobin concentration rose above
12 g/dl. Dosage increases were most frequent in Group 3, less
common in Group 2, and rare in Group 1. Reductions in the dose
of EPO were slightly more frequent in Group 1 compared with
Group 2, and were completely absent in Group 3 (Table 2).
Hemoglobin response
The hemoglobin response in Group I was significantly greater
than that in the other two groups (Fig 1). This difference became
evident at 8 weeks, and persisted throughout the remainder of the
study period. There was no significant difference in the hemoglo-
bin response between Groups 2 and 3 at any of the time points
throughout the study. There was a slightly enhanced rcticulocyte
response in Group 1 compared with the other two groups at the
start of EPO treatment, but this was not statistically significant
(data not shown).
Serum ferritin levels
The serum ferritin levels remained fairly constant in Group 1,
the mean values being maintained at around 300 to 400 pg/liter
(Fig 2). In contrast, there was a progressive fall in serum ferritin
in the other two groups to a level of around 100 to 200 pg/liter.
The mean serum ferritin for Group 2 became significantly lower
than that for Group I at 8 weeks and this was maintained for the
remainder of the study. Similarly, the ferritin levels in Group 3
were significantly less than in Group 1 at 12 and 16 weeks. There
were no significant differences in serum ferritin between Groups 2
and 3 at any time points throughout the study.
Transferrin saturation
There was no difference in the mean serum iron, TIBC, or
transferrin saturation among the three groups prior to EPO
therapy. The transferrin saturation, however, fell in all the groups
after EPO was started; this was due to a decrease in serum iron,
the TIBC remaining relatively constant (Table 3). The fall in
serum iron and transferrin saturation was greater in Groups 1 and
3 than in Group 2, and was evident within four weeks of EPO
treatment.
EPO dosage requirements
The mean weekly dose of EPO in Group 1 remained fairly
constant at around 75 U/kg throughout the four months of the
study (Fig. 3). Slightly, but not significantly, higher doses were
Table 2. Number of adjustments in EPO dose required in the 3 groups
of patients, with (in brackets) the weeks in which the changes were
made
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Fig. 2. Serum ferritin concentrations (mean SD) in 3 groups of EPO-
treated patients. Symbols are: (•) iv. Fe; (U) No Fe; (0) Oral Fe; * p <
0.05, P < 0.005, P < 0.0005 vs. iv. Fe treated group.
6
0 4 8 12 16
Time, weeks
Fig. 1. Hemoglobin response (mean SD) in 3 groups of EPO-treated
patients with different regimens of iron supplementation. Symbols are: (•) iv.
Fe; (0) Oral Fe; (U) No Fe; * p < 0.05, * * P < 0.005 vs. iv. Fe treated
group.
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Table 3. Serum iron, TIBC, and transferrin saturation in 3 groups of
patients on EPO receiving different regimens of iron supplementation
Weeks on EPO
0 4 8 12 16
Serum iron
j.unol/liter
i.v. Fe
Oral Fe
No Fe
14 (4)
13 (2)
13 (4)
7 (2)
13 (2)'
8 (3)'
9 (2)
12(2)
7 (3)'
12 (4)
11(3)
8 (3)
12 (2)
15 (4)
9 (3)C
Serum TIBC
unol/liter
iv. Fe
Oral Fe
NoFe
55 (8)
50(10)
59(7)
52 (6)
53 (10)
57(11)
50 (4)
48(12)
56(11)
48 (7)
53 (14)
56(10)
52 (4)
46(11)
58(8)
Transferrin
saturation %
iv. Fe
Oral Fe
No Fe
26 (9)
27 (11)
23 (5)
14 (2)
25 (10)
15 (5)
18 (4)
24(5)
12 (3)"'
24 (7)
22(3)
15 (5)
23 (4)
31(4)
15 (6)"
l  
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Fig. 4. Individual total doses of EPO used during the 16-week study period
in the 3 groups of patients.
Group 1, £815 for Group 2, and £929 for Group 3. The total cost
of i.v. iron for each patient in Group I was £26. Thus, the use of
i.v. iron allowed a saving of £32 per patient compared with the use
of oral iron, and £146 per patient compared with no iron
supplementation. This should be viewed in the light of an
enhanced hemoglobin response in Group 1, and since patients in
this group had reached their desired hemoglobin in contrast to
many of the patients in Groups 2 and 3, further cost-savings would
be anticipated following the completion of the study at 16 weeks.
Discussion
This study shows that patients given regular intravenous iron
have an enhanced hemopoietic response to EPO compared with
those given oral iron supplements or no iron at all. This response
was achieved with maintenance of the serum ferritin at relatively
constant levels, and the use of marginally lower total amounts of
EPO.
Although the results for the group receiving i.v. iron were
superior to those given oral iron supplements, one possible
weakness of the study may be that compliance might have been
incomplete in the group taking oral iron supplements. However,
the importance of taking all tablets was emphasized repeatedly to
all patients, and monitored closely at each clinic visit. In addition,
because of the attention we paid to encouraging compliance, it is
likely that we achieved the best compliance possible in a group of
patients on EPO. Thus, for practical purposes, even if compliance
was not 100%, the level achieved could almost certainly not be
bettered in routine clinical practice. Dietary intake of iron was not
formally assessed in this study since the amounts ingested would
be trivial compared with the amounts contained in the oral and
intravenous iron preparations.
The serum iron levels and transferrin saturation were better
maintained in the group receiving oral iron compared with that
Results are expressed as means (SD).
P < 0.05 vs i.v. Fe
h P < 0.005 vs iv. Fe
P < 0.05 vs Oral Fe
d P < 0.005 vs Oral Fe
150
100
Ci)
Cd)0
0
a-
w
0
Time, weeks
Fig. 3. Weekly EPO dosage requirements (mean SD) in 3 groups of
patients. Symbols are: (U) No Fe; (0) Oral Fe; (•) iv. Fe; * < 0.05,
**p < 0.01 vs. i.v. Fe treated group.
used in Group 2, and Group 3 received the highest doses of all.
This was statistically significant at 12 and 16 weeks when compar-
ing Groups I and 3.
The total amount of EPO used by each patient during the four
months of the study is shown in Figure 4. The dosage require-
ments were less in Group 1 (1202 229 UIkg/16 weeks) than in
Group 2 (1294 314 U/kgIl6 weeks) or Group 3 (1475 311
U/kgIl6 weeks; P < 0.05 vs. Group 1 (Fig. 4).
Cost-benefit analysis
For the duration of the study, a total of 1,009,400 units of EPO
was used for the patients in Group 1, compared with 1,177,750
units for Group 2, and 1,239,000 units for Group 3. At the prices
quoted for EPO and i.v. iron dextran when the study was
performed, this represents a total cost of £9,084 for Group 1,
£10,599 for Group 2, and £11,151 for Group 3. The average cost
of EPO per patient for the 16 weeks of the study was £757 for
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given i.v. iron. This is probably due to the fact that the latter group
received intermittent large holuses of iron which had already been
utilized and cleared from plasma during the two weeks prior to
blood sampling, in contrast to the continuous mode of adminis-
tration of the oral iron, it also casts further doubt on the validity
of the transferrin saturation measurement, since the "i.v. iron"
group achieved the optimum hemoglobin response despite run-
ning low transfcrrin saturations from weeks 4 to 8.
it is interesting to speculate as to why treatment with i.v. iron
was so superior to oral iron supplementation. Previous studies
have shown that, following infusion, iron dextran is rapidly
metabolized, and the iron is released into the reticulo-endothelial
system [20]. This iron is then immediately available for erythro-
poicsis [21]. The bioavailability of oral iron is less clear cut, and in
particular iron absorption from the gut may be unreliable. There
is currently some controversy over whether oral iron is well-
absorbed in renal patients receiving EPO. Earlier studies sug-
gested that iron absorption was enhanced in dialysis patients who
were iron-deficient [22, 23]. Skikne and Cook [24] also found that
iron absorption was increased by EPO therapy in normal healthy
volunteers, although two studies have suggested impaired absorp-
tion in dialysis patients on EPO [25, 26]. Thus, although iron
absorption would appear to he enhanced in absolute iron defi-
ciency, the situation is less clear in patients who arc functionally
iron-deficient (that is, normal iron stores, hut an inability to
release iron rapidly enough to satisi the demands of the marrow).
All the patients in this study were iron-replete with an initial
serum ferritin > 100 gg/liter, and thus it is possible that iron
absorption in this cohort of patients was impaired.
The fact that it was possible to enhance erythropoiesis with
intravenous iron supplementation in this group of iron-replete
patients suggests that iron supply to the marrow is a rate-limiting
step in the process of ciythropoiesis. It seems apparent that
regular oral iron supplementation is unable to produce this effect,
almost certainly due to differences in hioavailahility between
orally- and intravenously-administered iron. The lack of any
significant benefits of oral iron compared with no iron supplemen-
tation was surprising, and suggests that there is no great advantage
in patients with initial serum ferritin levels > 100 1Zglliter taking
oral iron supplements, other than a possible slight saving in EPO
dosage requirements. However, it is possible that once the serum
ferritin level falls with EPO treatment, the hioavailability of oral
iron may increase, and there may then be a role for oral iron
supplements.
The regimen for administering intravenous iron in this study
was arbitrary, and there is no evidence that fortnightly infusions of
5 ml iron dextran represent the optimum method. We selected
this regimen since it was practical (the patients were attending for
review on a fortnightly basis, and it was convenient to give one vial
of 5 ml iron dextran at each visit). The fact that the mean serum
fcrritin levels did not change appreciably during the study suggests
that all the intravenous iron given was being consumed in the
process of erythropoiesis, since any excess of iron would have
been reflected in a rise in serum ferritin. It would clearly have
been possible to give the entire 40 ml of iron dextran (analogous
to a total dose iron infusion) at the start of EPO therapy although
there is no guarantee that it would have had the same effect.
There are theoretical reasons, however, why the more frequent,
lower-dose regimen might be preferable. Administering a large
single holus of parenteral iron would result in all but a small
fraction ending up in reticulo-endothelial stores. There may
theoretically be difficulties in releasing the iron from these stores
again when it is needed, since many factors such as infection and
inflammatory disease can interfere with this process 127]. Large
holuscs of intravenous iron also commonly cause arthralgia and
other side-effects [28]. Giving frequent but smaller bnluses en-
sures a slow but steady supply of readily available iron to the
marrow.
The results from this study suggest that it may be cost-effective
to use intravenous iron supplementation more widely in patients
commencing FF0, considering the relative costs of EPO and iron
dextran. The present evidence suggests that this is valid even in
the absence of any laboratory evidence of iron insufficiency.
However, this has to be weighed against the disadvantages of
adopting a "regular i.v. iron" protocol, namely the time and labor
involved in setting up and supervising the iron infusions, the
inconvenience to the patient of regular visits to the hospital, and
the small hut significant risk of serious adverse effects such as
anaphylactic reactions. Furthermore, this study sought to investi-
gate the potential benefits of intravenous iron supplementation in
the correction phase of EPO therapy only; it would be inappro-
priate to extrapolate these conclusions to the maintenance phase
of treatment, which would require a separate study.
In any patient who is responding poorly to FF0 in the absence
of any identifiable cause, however, it would seem reasonable to
consider a trial of intravenous iron supplementation, with close
monitoring of the subsequent response. Although there is some
concern regarding allergy and anaphylactic reactions to iron
dextran, other parentcral iron compounds are becoming more
widely available [29], which are likely to share the same benefits in
terms of enhancing the response to EPO.
Reprint requests to Dr 1. C Macdougall, Consultant Nephrolagist, Renal
Unit, Kingc College and Dulwich Hospitals, East Dulwich Grove, London
SE22 8PT England, United Kingdom.
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